Paysign, Inc. Applauds Preliminary Injunction of Plasma Ban

Rhea-AI Summary

Paysign, Inc. (NASDAQ: PAYS) announced that the U.S. District Court issued a preliminary injunction on September 16, 2022, allowing plasma donations from Mexican nationals on valid B-1/B-2 visas. CEO Mark Newcomer praised the decision, emphasizing its significance for plasma clients and therapies for rare diseases. Paysign is a leader in prepaid card programs and digital banking services, focused on creating innovative payment solutions across various industries.

Positive

• U.S. District Court's injunction allows plasma donations from Mexican nationals, enhancing donor pool.
• Increased plasma donations could boost client operations and supply for rare disease therapies.

Negative

• None.

HENDERSON, Nev.--(BUSINESS WIRE)-- Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced that on September 16, 2022, the United States District Court issued a preliminary injunction preventing the United States Customs and Border Protection (CBP) from continuing to enforce its ban on plasma donations by Mexican nationals.

“Paysign applauds this decision as it allows our plasma clients to resume accepting plasma donations from Mexican nationals who enter the U.S. on a valid B-1/B-2 visa,” said Mark Newcomer, Paysign CEO. “Paysign would like to welcome back these donors and we appreciate their contribution to the supply of source plasma, which is used in therapies to treat a variety of rare diseases worldwide.”

About Paysign

Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers and government institutions. Founded in 2001 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign’s end-to-end technologies securely enable digital financial services and facilitate the distribution of funds for donor compensation, copay assistance, payroll, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. Paysign’s solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220927005375/en/

Paysign Investor Relations

888.522.4810

ir@paysign.com

paysign.com/investors

Paysign Media Relations

Alicia Ches, Director of Marketing

702.749.7257

pr@paysign.com

Source: Paysign, Inc.

FAQ

What did the U.S. District Court decide about plasma donations on September 16, 2022?

The court issued a preliminary injunction allowing plasma donations from Mexican nationals with valid B-1/B-2 visas.

How does Paysign benefit from the court's decision regarding plasma donations?

The decision expands the donor pool for Paysign's clients, potentially increasing plasma supply for rare disease therapies.

What is the stock symbol for Paysign, Inc.?

The stock symbol for Paysign, Inc. is PAYS.

What type of services does Paysign offer?

Paysign provides prepaid card programs, patient affordability offerings, digital banking, and integrated payment processing.